Research analysts at UBS Group began coverage on shares of Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) in a report released on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating and a $2.00 price target on the stock. UBS Group‘s price target indicates a potential upside of 455.40% from the company’s previous close.
A number of other research firms have also weighed in on ENSC. Cantor Fitzgerald assumed coverage on Ensysce Biosciences in a report on Tuesday, October 20th. They set an “overweight” rating and a $2.00 target price on the stock. Wall Street Zen raised Ensysce Biosciences to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings raised shares of Ensysce Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ensysce Biosciences currently has a consensus rating of “Hold” and a consensus target price of $2.00.
Read Our Latest Stock Report on Ensysce Biosciences
Ensysce Biosciences Stock Up 0.0%
Shares of NASDAQ ENSC opened at $0.36 on Thursday. The business’s 50 day moving average price is $0.45 and its two-hundred day moving average price is $0.42. The company has a market cap of $7.01 million, a PE ratio of -0.13 and a beta of 1.11. Ensysce Biosciences has a twelve month low of $0.23 and a twelve month high of $2.17.
Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). Ensysce Biosciences had a negative return on equity of 2,550.30% and a negative net margin of 280.53%. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.20 million. As a group, research analysts anticipate that Ensysce Biosciences will post -0.60 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Ensysce Biosciences stock. StoneX Group Inc. bought a new stake in Ensysce Biosciences, Inc. (NASDAQ:ENSC – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 138,563 shares of the company’s stock, valued at approximately $58,000. StoneX Group Inc. owned 0.71% of Ensysce Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 5.63% of the company’s stock.
Ensysce Biosciences Company Profile
Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing prescription medicines designed to address opioid abuse, misuse and overdose. The company’s technology is intended to preserve the therapeutic benefits of opioid pain medicines while incorporating mechanisms that may reduce the risks associated with tampering or excessive dosing. Ensysce’s lead product candidate, PF614, is an investigational extended-release oxycodone prodrug designed to be activated in the gastrointestinal tract.
Read More
- Five stocks we like better than Ensysce Biosciences
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
